Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.32%
+0.14%
-1.99%
-3.06%
SCLX
Scilex Holding Company
$17.35
Login to see Scilex Holding Company (SCLX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Chart
$22.17 (-21.74%)
$6.46 (+168.58%)
$4.19 (+314.08%)
$0.95 (+1726.32%)
SCLX has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
SCLX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
SCLX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SCLX Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displaySCLX Earnings
The TTM reflects 12-month period, providing review of SCLX financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is SCLX current stock price?
What are SCLX stock strengths?
What risks are associated with SCLX stock?
When is SCLX next earnings report?
What is SCLX market cap and volume?
What is SCLX's current Stock IQ?
Should I buy SCLX stock right now?
Is SCLX a Strong Buy right now?
What does a 'Strong Buy' rating mean for SCLX?
What does a 'Strong Sell' rating mean for SCLX?
What factors influence SCLX's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.32%
+0.14%
-1.99%
-3.06%
SCLX
Scilex Holding Company
Current Price
$17.35
Stock Insights
Strengths
Earnings are forecast to grow
Login to unlock Scilex Holding Company (SCLX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$22.17 (-21.74%)
$6.46 (+168.58%)
$4.19 (+314.08%)
$0.95 (+1726.32%)
SCLX Analysts Opinion
SCLX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
SCLX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SCLX Street view is extremely bullish and have negative views on the near-term outlook
SCLX has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
Average key support and resistance price levels.
Login to displaySCLX Earnings
The TTM data reflects the most recent 12-month period, providing overview of SCLX financial performance.
SCLX Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
SCLX Latest Analysis
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals Inc. Warrant Repurchase. PALO ALTO Calif. Oct. 01 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex or the Company) (Nasdaq: SCLX) an innovative revenue-generating company focused on acquiring developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease today announced that it has repurchased 3
Wed Oct 1, 2025
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI. PALO ALTO Calif. Sept. 26 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex or the Company) (Nasdaq: SCLX) an innovative revenue-generating company focused on acquiring developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease today announced that it has closed the initial tranche
Fri Sep 26, 2025
Datavault AI (DVLT) Touches $1 Level Anew After 4 Months on New $150-Million Investment. We recently published Massive Gains: 10 Stocks Investors Cant Stop Buying. Datavault AI Inc. (NASDAQ:DVLT) is one of the top performers on Thursday. Datavault rebounded on Thursday to test the $1 territory soaring 28.43 percent to close at $0.8348 apiece after securing a $150 million investment from Scilex Holding Company. During the session the company [….]
Fri Sep 26, 2025
Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals Inc. Held by Scilex Holding Company for $200 Million in Bitcoin. ) an innovative revenue-generating company focused on acquiring developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease today announce
Thu Sep 25, 2025
Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management.
Wed Sep 24, 2025
Semnur Pharmaceuticals Inc. (Semnur) a Majority Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX Scilex) Announces Signing of a Securities Purchase Agreement with an Institutional Investor for the Purchase of $100 Million of shares of Semnur Common Stock in Exchange for $100 Million in Bitcoin. PALO ALTO Calif. Sept. 23 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals Inc. (Semnur or the Company) (OTC: SMNRW)) a clinical late-stage specialty pharmaceutical company focused on the developm
Tue Sep 23, 2025
Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals Inc. Held By Scilex Holding Company for $200 Million in Bitcoin.
Tue Sep 23, 2025
Semnur Pharmaceuticals Inc. (Semnur) a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX Scilex) and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination. PALO ALTO Calif. Sept. 22 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex or the Company) (Nasdaq: SCLX) an innovative revenue-generating company focused on acquiring developing and commercializing non-opioid pain management products for the treatment of acute and chr
Mon Sep 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SCLX Stock trends
SCLX Stock performance
SCLX Stock analysis
SCLX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings